Net total incremental costs accrued through 100% detection of each high risk condition separately. 95% credible intervals obtained through probabilistic sensitivity analysis are shown in brackets
| 5 year horizon | 10 year horizon | 25 year horizon | ||||
| Current care management | NICE guidelines | Current care management | NICE guidelines | Current care management | NICE guidelines | |
| Hypertension | £0.69b (−£0.8b to £1.8b) | £2.9b (−£1.1b to £5.1b) | −£0.05b (−£3.8b to £2.2b) | £2.1b (−£6.5b to £7.4b) | −£1.9b (−£12.1b to £5.3b) | −£2.1b (−£22.0b to £10.7b) |
| High cholesterol/ QRISK≥10% | −£1.1b (−4.4b to £0.7b) | −£1.1b (−10.4b to £3.2b) | −£2.3b (−£9.3b to £1.7b) | −£3.8b (−£21.6b to £5.4b) | −£2.9b (−£17.2b to £7.8b) | −£2.9b (−£35.6b to £18.4b) |
| Diabetes | £0.49b (−£1.3b to £2.4b) | £2.6b (−£1.2b to £6.2b) | −£1.2b (−£6.8b to £3.4b) | £2.4b (−£7.7b to £11.5b) | −£56.7b (−£92.6b to −£29.9b) | −£49.3b (−£98.5b to −£17.3) |
| NDH | £2.2b (£1.1b to £3.0b) | £3.6b (£1.9b to £5.1b) | £2.1b (−£0.8b to £4.4b) | £3.7b (£0.4b to £6.5b) | £3.6b (−£7.1b to £13.3b) | £4.4b (−£4.1b to £17.6b) |
| AF | £0.39b (−£1.2b to £2.3b) | £1.1b (−£1.7b to £5.9b) | £0.9b (−£1.8b to £4.1b) | £2.1b (−£2.6b to £9.5b) | £2.5b (−£2.6b to £9.8b) | £4.7b (−£4.1b to £17.6) |
| CKD | −£0.32b (−£1.3b to £0.3b) | −£1.4b (−£4.3b to £0.5b) | −£0.53b (−£2.4b to £0.9b) | −£2.1b (−£6.8b to £1.2b) | −£0.42b (−£4.7b to £3.4b) | −£1.8b (−10.5b to £5.3b) |
AF, atrial fibrillation; CKD, chronic kidney disease; NDH, non-diabetic hyperglycaemia; NICE, National Institute for Health and Care Excellence.